AN ECONOMIC EVALUATION OF DASATINIB (SPRYCEL®) IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN CENTRAL AND EASTERN EUROPE

被引：1
|
作者：
Nagy, B. [1 ]
Kutikova, L. [2 ]
Stastny, M. [2 ]
Vasile, K. [3 ]
Nagy, Zsolnai, I [5 ]
Mayer, J. [4 ]
机构：
[1] Healthware Consulting Ltd, Budapest, Hungary
[2] Bristol Myers Squibb Co, Prague, Czech Republic
[3] Bristol Myers Squibb Co, Bucharest, Romania
[4] Univ Hosp Brno, Brno, Czech Republic
[5] Bristol Myers Squibb Co, Budapest, Hungary
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66231-6
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A358 / A358
页数：1
相关论文
共 50 条
  • [21] Phase II trial of dasatinib (DAS) in pediatric patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP).
    Gore, Lia
    Kearns, Pamela
    Lee, Maria Lucia
    De Souza, Carmino Antonio
    Bertrand, Yves
    Hijiya, Nobuko
    Stork, Linda C.
    Chung, Nack-Gyun
    Cardenas-Cardos, Rocio
    Saikia, Tapan
    Fagioli, Franca
    Seo, Jong-Jin
    Landman-Parker, Judith
    Lancaster, Donna
    Place, Andrew E.
    Rabin, Karen R.
    Sacchi, Mariana
    Swanink, Rene
    Zwaan, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Resistance, Outcome and the Development of Mutations with Dasatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).
    Shah, Neil
    Bahceci, Erkut
    Lambert, Alexandre
    Ploughman, Lynn
    Radich, Jerald
    BLOOD, 2009, 114 (22) : 460 - 460
  • [23] Low Risk of Infectious Events in Patients (Pts) with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib
    Al-Ameri, Ali M.
    Kantarjian, Hagop
    Burton, Elizabeth
    O'Brien, Susan
    Ravandi, Farhad
    Borthakur, Gautam
    Walker, Brenda
    Rios, Mary Bath
    Cortes, Jorge
    BLOOD, 2009, 114 (22) : 1275 - 1275
  • [24] Cardiovascular Hospitalization in Patients Treated with Dasatinib or Nilotinib in Simplicity, an Observational Study of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients in Routine Clinical Practice
    Mauro, Michael J.
    Chen, Clara
    Cortes, Jorge E.
    Gambacorti-Passerini, Carlo
    Sen, Ginny P.
    Gajavelli, Srikanth
    Davis, Catherine
    Michallet, Mauricette
    BLOOD, 2018, 132
  • [25] Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily
    Shah, N. P.
    Cortes, J. E.
    Schiffer, C. A.
    le Coutre, P.
    Bahceci, E.
    Lambert, A.
    Saglio, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] Cytogenetic and Molecular Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in a Prospective Observational Study (SIMPLICITY)
    Mauro, Michael
    Gambacorti-Passerini, Carlo
    Goldberg, Stuart L.
    Cortes, Jorge E.
    Khoury, H. Jean
    Michallet, Mauricette
    Paquette, Ronald
    Simonsson, Bengt
    Turner, Michelle P.
    Mohamed, Hesham
    Subar, Milayna
    Zyczynski, Teresa
    BLOOD, 2014, 124 (21)
  • [27] Epic: A Phase 3 Trial of Ponatinib Compared with Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CP-CML)
    Lipton, Jeffrey H.
    Chuah, Charles
    Guerci-Bresler, Agnes
    Rosti, Gianantonio
    Simpson, David
    Assouline, Sarit
    Etienne, Gabriel
    Nicolini, Franck E.
    Le Coutre, Philipp
    Clark, Richard
    Stenke, Leif
    Andorsky, David
    Oehler, Vivian
    Lustgarten, Stephanie
    Rivera, Victor M.
    Clackson, Tim
    Haluska, Frank G.
    Baccarani, Michele
    Cortes, Jorge E.
    Guilhot, Francois
    Hochhaus, Andreas
    Hughes, Timothy P.
    Kantarjian, Hagop M.
    Shah, Neil P.
    Talpaz, Moshe
    Deininger, Michael W.
    BLOOD, 2014, 124 (21)
  • [28] Efficacy and Safety Of Ponatinib Following Failure Of Nilotinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML) In The PACE Trial
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Kim, Dong-Wook
    Pinilla-Ibarz, Javier
    le Coutre, Philipp D.
    Paquette, Ronald
    Chuah, Charles
    Nicolini, Franck E.
    Apperley, Jane F.
    Khoury, H. Jean
    Talpaz, Moshe
    DiPersio, John F.
    DeAngelo, Daniel J.
    Abruzzese, Elisabetta
    Rea, Delphine
    Baccarani, Michele
    Mueller, Martin C.
    Gambacorti-Passerini, Carlo
    Lustgarten, Stephanie
    Rivera, Victor M.
    Clackson, Tim
    Turner, Christopher D.
    Haluska, Frank G.
    Guilhot, Francois
    Deininger, Michael W.
    Hochhaus, Andreas
    Hughes, Timothy P.
    Goldman, John M.
    Shah, Neil P.
    BLOOD, 2013, 122 (21)
  • [29] Dasatinib (SPRYCEL®) vs escalated dose of imatinib (im) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib:: Results of the CA180-017 START-R randomized study.
    Shah, Neil
    Pasquini, R.
    Rousselot, P.
    Jootar, S.
    Holowiecki, J.
    Countouriotis, A.
    Dejardin, D.
    Hughes, T.
    Druker, Brian J.
    BLOOD, 2006, 108 (11) : 53A - 54A
  • [30] Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving dasatinib 100mg once daily
    Le Coutre, P.
    Shah, N.
    Cortes, J. E.
    Schiffer, C.
    Bahceci, E.
    Lambert, A.
    Saglio, G.
    ONKOLOGIE, 2010, 33 : 82 - 82
12345